Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs
Triveni Bio raises $65M ahead of upcoming readouts on its eczema drug programs, advancing its antibody-based pipeline for immune and inflammatory diseases.
Triveni Bio
Private
Triveni Bio is a private clinical-stage biotechnology company developing novel antibody therapeutics for immune and inflammatory diseases using a genetics-informed precision medicine approach. The company raised $65M in June 2026 ahead of upcoming readouts on its lead eczema drug programs, advancing first-in-class functional antibodies for I&I disorders with defined genetic patient stratification strategies.
Company Info
Sector: Biotechnology / Antibody Therapeutics / Immunology
Headquarters: Watertown, Massachusetts, USA
Founded: 2019
Website: triveni.bio/
Funding Round: Series C June 2026 ($65M)
Total Funding: $200M+ (cumulative private financing)
Funding & Investor Relations
Notable Investors
- Atlas Venture
- OrbiMed
- Surveyor Capital
- Cormorant Asset Management
- Samsara BioCapital
- Osage University Partners
IPO Outlook / Plans
None publicly disclosed; clinical-stage immunology biotech with readouts anticipated.
Upcoming Milestones & Key Dates
H2 2026
Clinical Trial
Phase 2 readout for TRIV-509 in atopic dermatitis / eczema
Clinical Development Pipeline
TRIV-509 (anti-IL-18 / IL-18BP pathway)
Target: IL-18 binding protein (IL-18BP) modulationUndisclosed antibody
Target: Genetics-defined IBD pathwayUndisclosed antibody
Target: Genetics-defined inflammatory pathwayRecent News
Leadership Team
To be confirmed
Chief Executive Officer
Kejie Li
Head of Data Science
To be confirmed
Chief Medical Officer
Careers & Job Openings